You are here

Aimmune

NICE backs Aimmune’s peanut allergy drug Palforzia for children

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Pharmaforum

Flag link:

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Endpoints

Flag link:

Aimmune Becomes Point Pharmaceutical Business for Nestlé

Aimmune Becomes Point Pharmaceutical Business for Nestlé

BioSpace

Flag link:

Gilead rescues biopharma’s takeout scene

Gilead rescues biopharma’s takeout scene

EP Vantage

Gilead Sciences

Momenta Pharmaceuticals

Principia Biopharma

Tizona Therapeutics

Flag link:

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

Endpoints

Flag link:

Nestle pays $2 billion to secure Aimmune’s allergy treatment

Nestle pays $2 billion to secure Aimmune’s allergy treatment

CNBC

Flag link:

In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions

In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions

Endpoints

DBV Technologies

Flag link:

What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline

What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline

Motley Fool

DBV Technologies

Flag link:

Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor

Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor

Fierce Biotech

Flag link:

Aimmune wins approval for peanut immunotherapy, charges 10k+

Aimmune wins approval for peanut immunotherapy, charges 10k+

Endpoints

Flag link:

FDA decision nears on Aimmune's contested peanut allergy drug

FDA decision nears on Aimmune's contested peanut allergy drug

BioPharma Dive

DBV Technologies

Flag link:

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Aimmune's peanut allergy drug secures FDA panel support, along with criticism

Biopharma Dive

Flag link:

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile

Endpoints

Flag link:

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Endpoints

Flag link:

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

Xconomy

DBV Technologies

Flag link:

Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment

Peanut allergy therapy scores trial win, putting it in line to possibly become first protective treatment

Stat

clinical trials

Flag link:

Aimmune's peanut allergy drug clears Phase II on the way to a pivotal test

Aimmune's peanut allergy drug clears Phase II on the way to a pivotal test

Fierce Biotech

clinical trials

Flag link:

Aimmune plots a $153M IPO to fund its 'breakthrough' food allergy pill

Aimmune plots a $153M IPO to fund its 'breakthrough' food allergy pill

Fierce Biotech

Flag link: